115 related articles for article (PubMed ID: 23635604)
1. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study.
Ojeda-Cervantes M; Barrera-Chimal J; Alberú J; Pérez-Villalva R; Morales-Buenrostro LE; Bobadilla NA
Am J Nephrol; 2013; 37(5):481-90. PubMed ID: 23635604
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone reduces oxidative stress in living donor kidney transplantation: a randomized controlled trial.
Morales-Buenrostro LE; Ortega-Trejo JA; Pérez-Villalva R; Marino LA; González-Bobadilla Y; Juárez H; Zamora-Mejía FM; González N; Espinoza R; Barrera-Chimal J; Bobadilla NA
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F519-F528. PubMed ID: 31241992
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients.
Thangaraj SS; Thiesson HC; Svenningsen P; Stubbe J; Palarasah Y; Bistrup C; Jensen BL; Mortensen LA
Am J Physiol Renal Physiol; 2022 Feb; 322(2):F138-F149. PubMed ID: 34894724
[TBL] [Abstract][Full Text] [Related]
4. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients.
Mortensen LA; Bistrup C; Stubbe J; Carlström M; Checa A; Wheelock CE; Palarasah Y; Bladbjerg EM; Thiesson HC; Jensen BL
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F529-F539. PubMed ID: 31166706
[TBL] [Abstract][Full Text] [Related]
5. Recovery from ischemic acute kidney injury by spironolactone administration.
Sánchez-Pozos K; Barrera-Chimal J; Garzón-Muvdi J; Pérez-Villalva R; Rodríguez-Romo R; Cruz C; Gamba G; Bobadilla NA
Nephrol Dial Transplant; 2012 Aug; 27(8):3160-9. PubMed ID: 22516623
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.
Luther JM; Gainer JV; Murphey LJ; Yu C; Vaughan DE; Morrow JD; Brown NJ
Hypertension; 2006 Dec; 48(6):1050-7. PubMed ID: 17043157
[TBL] [Abstract][Full Text] [Related]
7. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.
Mejía-Vilet JM; Ramírez V; Cruz C; Uribe N; Gamba G; Bobadilla NA
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F78-86. PubMed ID: 17376767
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Spironolactone on Acute Kidney Injury After Cardiac Surgery: A Randomized, Placebo-Controlled Trial.
Barba-Navarro R; Tapia-Silva M; Garza-Garcia C; López-Giacoman S; Melgoza-Toral I; Vázquez-Rangel A; Bazúa-Valenti S; Bobadilla N; Wasung de Lay M; Baranda F; Chawla LS; Gamba G; Madero M
Am J Kidney Dis; 2017 Feb; 69(2):192-199. PubMed ID: 27522513
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
Pitt B; Filippatos G; Gheorghiade M; Kober L; Krum H; Ponikowski P; Nowack C; Kolkhof P; Kim SY; Zannad F
Eur J Heart Fail; 2012 Jun; 14(6):668-75. PubMed ID: 22562554
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury.
Barrera-Chimal J; Pérez-Villalva R; Rodríguez-Romo R; Reyna J; Uribe N; Gamba G; Bobadilla NA
Kidney Int; 2013 Jan; 83(1):93-103. PubMed ID: 23014458
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
Morales E; Millet VG; Rojas-Rivera J; Huerta A; Gutiérrez E; Gutiérrez-Solís E; Egido J; Praga M
Nephrol Dial Transplant; 2013 Feb; 28(2):405-12. PubMed ID: 23222416
[TBL] [Abstract][Full Text] [Related]
12. Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress.
Chen H; Sun F; Zhong X; Shao Y; Yoshimura A; Liu Y
Kidney Blood Press Res; 2013; 37(6):557-66. PubMed ID: 24296802
[TBL] [Abstract][Full Text] [Related]
13. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy.
Takebayashi K; Matsumoto S; Aso Y; Inukai T
J Clin Endocrinol Metab; 2006 Jun; 91(6):2214-7. PubMed ID: 16569732
[TBL] [Abstract][Full Text] [Related]
17. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
[TBL] [Abstract][Full Text] [Related]
18. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial).
Mortensen LA; Thiesson HC; Tougaard B; Egfjord M; Fischer ASL; Bistrup C
BMC Nephrol; 2018 May; 19(1):105. PubMed ID: 29724188
[TBL] [Abstract][Full Text] [Related]
19. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.
Feniman-De-Stefano GM; Zanati-Basan SG; De Stefano LM; Xavier PS; Castro AD; Caramori JC; Barretti P; Franco RJ; Martin LC
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):158-67. PubMed ID: 26116627
[TBL] [Abstract][Full Text] [Related]
20. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Sato A; Hayashi K; Saruta T
Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
